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TGFb Signaling: Minireview
Receptors, Transducers,
and Mad Proteins
Joan Massague´ affinity binding (Letsou et al., 1995; Rosenzweig et al.,
1995).Cell Biology and Genetics Program
and Howard Hughes Medical Institute A central event in the generation of signals by these
complexes is phosphorylation of the type I receptor.Memorial Sloan–Kettering Cancer Center
New York, New York 10021 This is likely to be catalyzed by the type II receptor
kinase. The activity of this kinase is required for phos-
phorylation in the cell, and it phosphorylates recombi-
nant type I receptor in vitro (references can be found
The transforming growth factor b (TGFb) family of cyto- in Massague´ and Weis-Garcia, 1996). Phosphorylation
kines regulates cell proliferation, differentiation, recog- occurs in a cluster of five serine and threonine residues
nition, and death and figures prominently in the control in the GS domain, a highly conserved region next to the
of development, tissue recycling, and repair. The singu- N-terminus of the kinase domain in all type I receptors.
larity of the mechanisms that mediate these effects be- Mutation of these residues obstructs signaling, the se-
came manifest with the discovery, a few years ago, that verity of this defect being proportional to the number of
their membrane receptors are serine/threonine kinases. mutated residues. The type II receptors have kinase
This property sets them apart from other major classes activity that does not seem to be augmented by ligand
of hormone receptors. New insights into the mechanism binding. In essence, the ligand may be acting as an
of receptor activation and the implication of the Mad adaptor that brings a substrate—the type I receptor—to
(Mothers against dpp) gene family in TGFb signal trans- the primary receptor kinase.
duction emphasize the uniqueness of this signaling Key support for the idea that type I receptors act
network. downstream of the type II receptors is provided by the
phenotype of constitutively active mutant forms of the
type I receptors. Mutation to aspartate or glutamic acidA Kinase Cascade on the Membrane
in a particular residue of the GS domain endows TGFbThe TGFb family consists of groups of isoforms that
type I receptor (TbR-I) and other type I receptors withprogressively diverge from bone morphogenetic protein
elevated kinase activity and the ability to signal a range2 (BMP2) and BMP4 and their Drosophila counterpart,
of responses in the absence of ligand or type II receptorDecapentaplegic (DPP). In its bioactive form, each factor
(Wieser et al., 1995). Type I receptors activated this wayis a disulfide-linked dimer (usually a homodimer) whose
can signal even in the presence of a dominant-negativesubunits contain three disulfide bonds in a threaded-
type II receptor. Thus, once activated, the type I recep-ring configuration, or “cystine knot,” that provides a firm
tors can propagate the signal on their own.core. A mix of biochemical and genetic evidence has
The evidence to date argues that the type II receptorsshown that TGFb family members signal by simultane-
are unable to generate responses independently of theously contacting two transmembrane serine/threonine
type I receptors. In one report, however, overexpressionkinases known as the type I and type II receptors. Both
of an inactive TbR-II construct blocked a TGFb growthreceptor types are required for TGFb action in mamma-
inhibitory effect but not its effect on extracellular matrixlian cells (Wrana et al., 1994, and references therein) and
protein synthesis. Although this result suggested thatDPP action in Drosophila (Letsou et al., 1995; Ruberte
TbR-I and TbR-II might each signal separate responses,et al., 1995): mutations in either receptor type disrupt
other reports using similar test systems showed a losssignaling in each case.
of both responses. Reconciling these disparities, it hasAll plasma membrane serine/threonine kinases de-
been proposed that different TGFb responses may re-scribed to date in animal cells areTGFb family receptors.
quire different levels of signaling and thus be inhibitedFunctional analysis of these molecules has clarified, to
to varying degrees by a dominant-negative receptora first approximation, the basis for their collaborative
(Feng et al., 1995).involvement in the initiation, propagation, and diversifi-
cation of TGFb signals. Based on sequence similarities,
these proteins fall into two subfamilies that coincide A Combinatorial System Underlying
Signal Diversitywith the functional division between type II and type I
receptors. The type II receptors act upstream of type I Why signaling through two sequential transmembrane
kinases? For one, this system gives the ligand directreceptors, and so one may think of these components
as primary receptors and transducers, respectively. One control over signal diversity. Each ligand may recognize
different type II receptors and type I receptors, whichdifference between the two is in their ligand binding
properties. The type II receptors for TGFb and activin pair in a combinatorial manner (Figure 2) (for references
see Massague´ and Weis-Garcia, 1996). The nature ofrecognize these ligands free in the medium, whereas
their type I receptors do not. The type I receptors recog- the signal depends on the composition of the receptor
complex and, in particular, on the specificity of the type Inize ligand-bound type II receptor, forming an oligo-
meric complex, probably a heterotetramer (Figure 1). receptor kinase. For example, TbR-I and ActR-IB, which
have nearly identical kinase domains, can generate theThe BMP receptor system is somewhat different. In this
case, the type II receptors and the type I receptors both same set of responses even though their respective
ligands, type II receptors, and extracellular domains arehave low affinity for the ligand and together achieve high
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Figure 1. Steps in TGFb Receptor Activation
and Signal Transduction
quite different. Conversely, the responses generated by dorsalization and formation of gut, eye, and external
appendages. In the case of AMH/MIS, which inducesa ligand may differ depending on the choice of type I
receptor. Mu¨llerian duct regression during mammalian male de-
velopment, firm identification of its receptor was basedBy promoting the pairing of specific receptor combi-
nations, the ligand enforces specificity and control over on the finding of mutant AMHR alleles that cause a sex
differentiation defect similar to that caused by geneticthese interactions. As it turns out, the type II receptors
have affinity for the type I receptors, which is manifest loss of the ligand (for references see Massague´ and
Weis-Garcia, 1996).in their ability to associate spontaneously when overex-
pressed in cells, coincubated in solution, or tested as
cytoplasmic domain constructs in a yeast two-hybrid
system. Receptors and type I receptors that would nor- Mad Genes in the Pathway
Which are the components that turn these receptor sig-mally not associate in the cell do so under these condi-
tions. At physiological receptor levels, however, the as- nals into specific responses? A genetic approach to this
problem in Drosophila has yielded an important clue insembly of signaling complexes seems to be strictly
ligand dependent. the finding of Mad. This gene was uncovered in a screen
for modifiers of DPP activity, and its function is requiredThe assignment of particular responses to a given
ligand–receptor combination must often rely on a suit- for DPP activity in many aspects of development (Sekel-
sky et al., 1995). Using Mad transgenes regulated byable genetic system. This is not always available, a fact
reflected in the incompleteness of Figure 2. The precise tissue-specific enhancers, it has been shown that MAD
is required in cells receiving the DPP signal (Newfeld etreceptor combinations that mediate each activin or BMP
response remain tentative for this reason (Matzuk et al., al., 1996). Furthermore, overexpression of MAD partially
rescues DPP deficiencies (Wiersdorff et al., 1996). Deci-1995). On the other hand, genetic and other evidence
shows that the TbR-II/TbR-I combination mediates re- sive evidence for a role of MAD in DPP signaling comes
from the finding that null alleles of Mad suppress thesponses to several mammalian TGFb isoforms and that
the DPP type II receptor Punt, in concert with the type dominant phenotype of constitutively active thick veins
alleles (Hoodless et al., 1996; Wiersdorff et al., 1996).I receptors Thick veins or Saxophone, mediates embryo
Figure 2. Ligand–Receptor Combinations
and Their Known Effects
The TGFb family tree lists only representative
members of each cluster of isoforms. All the
components listed are mammalian except
DPP and its receptors.
Minireview
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Figure 3. Domain Structure of Mad Proteins
and Similarity among Family Members
The structures are aligned based on a highly
conserved N-terminal motif (LVKKLKK). The
level of identity refers to the combined N- and
C-domains and excludes other regions.
That is to say, MAD functions downstream of the DPP ventral mesoderm may involve a distinct isoform more
potent than Xmad1. Along the same lines, Sma-2,receptor.
The search for MAD-related molecules in other organ- Sma-3, and Sma-4 do not appear to mediate Daf-4 regu-
lation of dauer larva formation. It is possible that differentisms has turned up several homologs in Caenorhabditis
elegans, Xenopus laevis, mouse, and human. Work in responses to the same factor may bemediated by differ-
ent Mads and that the signaling specificity of a ligandthe nematode has focused on signaling by Daf-4, a BMP
receptor that controls dauer larva formation, body size, is dictated not only by the receptor isoforms, but also
by the profile of Mad isoforms expressed in the targetand tail sensory ray development. Screening for muta-
tions in the latter two processes led to the identification cell.
of sma-2, sma-3, and sma-4, three genes encoding ho-
mologs to Drosophila MAD (Savage et al., 1996). Genetic
analyses suggest that Sma-2 and Daf-4 act in the same Regulation and Function of Mad Proteins
The primary structure of Mad proteins does not containcells and that daf-4 expression does not bypass sma-2
mutations, all of which is consistent with a role of Sma any motif that would reveal their function. Mads are
proteins of z450 amino acids with highly conserveddownstream of Daf-4. Since the three sma genes act in
the same cell and have nonredundant functions, it has N-terminal and C-terminal domains and a variable pro-
line-rich intervening region (Figure 3). Intriguingly, all thebeen proposed that their products may act coopera-
tively, perhaps as a complex (Savage et al., 1996). described null mutations in Mad, sma2, and sma3 are
missense or nonsense mutations that fall within a highlySeveral Xenopus cDNAs have been cloned by homol-
ogy to Drosophila Mad, and two of them, Xmad1 and conserved, short portion of the C-domain (Savage et
al., 1996; Sekelsky et al., 1995). Mutations in this hotXmad2, have been described in detail (Graff et al., 1996;
Thomsen,1996). Both areubiquitously expressed during spot have also surfaced in DPC4 (deleted in pancreatic
carcinoma), a human Mad identified as a candidate tu-early development. At later stages, Xmad1 becomes
restricted to neural tissue contiguous to regions of mor suppressor in human chromosome 18q21.1 that is
mutated or deleted in half of all pancreatic malignanciesBMP2 and BMP4 expression. The activity of these pro-
teins has been revealed in Xenopus embryo assay sys- (Hahn et al., 1996). TGFb, activins, and BMPs can cause
cell cycle arrest, terminal differentiation, or apoptosis intems. Xmad1 mRNA injection into early-stage Xenopus
embryos mimics the ability of BMP4 to produce ventral different cell types, and DPC4 might be essential for
some of these responses.mesoderm. The same effect is observed with the corre-
sponding human homolog, Smad1 (Liu et al., 1996), and Smad1, also called Madr1 (the Mad nomenclature
needs unification and revision), undergoes two strikingwith Drosophila MAD (Newfeld et al., 1996). Xmad1 can
also reverse the neuralizing effect of dominant-negative modifications in response to BMP2 or BMP4: serine
phosphorylation (Hoodless et al., 1996) and accumula-BMP receptor, further suggesting that Xmad1 and
Smad1 are mediators of BMP signals. tion in thenucleus (Hoodless et al., 1996; Liu et al., 1996).
Both events are rapidly induced by BMP2 or BMP4 andIn contrast with the BMP-like effects of Xmad1,
Xmad2 transcripts mimic the ability of activin or Vg1 to require BMP receptors. TGFb induces phosphorylation
of products immunologically related to Madr1/Smad1,produce dorsal mesoderm in animal caps (Graff et al.,
1996). The same effect is observed with the mouse indicating the generality of this phenomenon (Lechleider
et al., 1996; Yingling et al., 1996). Madr1/Smad1 phos-Xmad2 homolog, Madr2, which was cloned in a screen
for mouse cDNA transcripts that can change the fate of phorylation is prevented by a missense mutation in a
hot spot glycine (Hoodless et al., 1996). It is presentlyXenopus ectoderm into mesoderm (Baker and Harland,
1996). Additionally, Madr2 mimics the ability of activin unclear whether phosphorylation is catalyzed by the
receptor kinase or an intermediate kinase or is second-to generate a secondary axis when injected into ventral
blastomeres at the 4-cell stage. One point made by ary to entry into the nucleus. The subcellular localization
of hot spot mutants may help clarify this question.these results is that different TGFb family members may
signal through different Mad isoforms. It is also notewor- A correlation between nuclear localization and Mad
function has been observed using Xenopus embryothy that the amount of Xmad1 transcript required to
prevent neuralization is much less than that required to assay systems (Baker and Harland, 1996). In the second-
ary axis generated by injected lacZ-tagged Madr2induce ventral mesoderm (Thomsen, 1996). One reason
for this could be that different responses may require mRNA, the protein is exclusively nuclear in cells of the
anterior portion of the axis and is cytoplasmic in otherdifferent signal thresholds. Another is that induction of
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Letsou, A., Arora, K., Wrana, J.L., Simin, K., Twombly, V., Jamal, J.,cells. Coinjection with activin mRNA enhances the nu-
Staehling-Hampton, K., Hoffmann, F.M., Gelbart, W.M., Massague´,clear localization of lacZ–Madr2. Based on these re-
J., and O’Connor, M.B. (1995). Cell 80, 899–908.sults, it has been suggested that when Madr2 is in the
Liu, F., Hata, A., Baker, J., Doody, J., Ca´rcamo, J., Harland, R., andcorrect embryonic context to respond to mesoderm-
Massague´, J. (1996). Nature, 381, 620–623.
inducing signals, it sensitizes the cells to these signals,
Massague´, J., and Weis-Garcia, F. (1996). In Cancer Surveys, T.
accumulates in the nucleus, and induces dorso–anterior Pawson and P. Parker, eds. (London: ICRF Press), 381, 620–623.
fate (Baker and Harland, 1996). Interestingly, the
Matzuk, M.M., Kumar, T.R., and Bradley, A. (1995). Nature 374,
C-domains of Madr2 and Smad1 mimic the activity of 356–359.
their full-length counterparts in mesoderm induction Newfeld, S.J., Chartoff, E.H., Graff, J.M., Melton, D.M., and Gelbart,
assays (Baker and Harland, 1996; Liu et al., 1996). Fur- W.M. (1996). Development, in press.
thermore, a lacZ-tagged Madr2 C-domain becomes lo- Rosenzweig, B.L., Imamura, T., Okadome, T., Cox, G.N., Yamashita,
calized in the nucleus of all cells expressing it (Baker H., ten Dijke, P., Heldin, C.-H., and Miyazono, K. (1995). Proc. Natl.
Acad. Sci. USA 92, 7632–7636.and Harland, 1996). The C-domain might be an active
domain, whereas the N-domain might act as an inhibitor Ruberte, E., Marty, T., Nellen, D., Affolter, M., and Basler, K. (1995).
Cell 80, 889–897.of nuclear translocation, a direct repressor of the
Savage, C., Das, P., Finelli, A., Townsend, S.R., Sun, C.-Y., Baird,C-domain, or both.
S.E., and Padgett, R.W. (1996). Proc. Natl. Acad. Sci. USA 93,What is it that Mads do once they enter the nucleus?
790–794.It has been observed that the C-domains of Smad1 and
Sekelsky, J.J., Newfeld, S.J., Raftery, L.A., Chartoff, E.H., and Gelb-DPC4 display transcriptional activity when bound to
art, W.M. (1995). Genetics 139, 1347–1358.
DNA via a GAL4 DNA-binding domain (Liu et al., 1996).
Thomsen, G. (1996). Development, in press.This activity is eliminated by a hot spot nonsense muta-
Wiersdorff, V., Lecuit, T., Cohen, S.M., andMlodzik, M. (1996). Devel-tion found in various Mad and DPC4 alleles. A full-length
opment, in press.
Smad1 fusion product is inactive in this assay, but can
Wieser, R., Wrana, J.L., and Massague´, J. (1995). EMBO J. 14, 2199–
be specifically activated in response to BMP2 or BMP4 2208.
in combination with BMP receptors. Thus, as in the nu-
Wrana, J.L., Attisano, L., Wieser, R., Ventura, F., and Massague´, J.
clear localization assays, an activity of the C-domain (1994). Nature 370, 341–347.
appears to be repressed by the N-domain and this re- Yingling, J.M., Das, P., Savage, C., Zhang, C., Padgett, R.W., and
pression eliminated by incoming BMP signals. These Wang, X.-F. (1996). Proc. Natl. Acad. Sci. USA, in press.
observations raise the possibility that the function of
Mad proteinsmight have something to do with the ability
to transactivate. Before this can be established, how-
ever, it will be necessary to demonstrate that native Mad
proteins can physically interact with specific response
elements in physiological target genes and that they
can activate transcription of these genes in response
to receptor signals. Once activated, Mads might interact
with other transcriptional regulators, possibly including
homologs of schnurri, a Drosophila transcription factor
genetically implicated in DPP signaling (Arora et al.,
1995; Grieder et al., 1995).
In sum, TGFb signaling continues to unfold as a clas-
sic process to bring to the nucleus instructions dictated
from the cell surface and shaped in the cytoplasm. The
advent of Mad proteins gives us an additional handle
on the components that mediate the diverseand remark-
able effects of the TGFb family.
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